Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 1.00 |
| ▸ | TACR3 | P29371 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | RHOC | P08134 | 1/20 | 0.46 |
| ▸ | RHOA | P61586 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297226 | 1.00 | TACR1 (1.00) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL8291732 | 0.89 | TACR1 (0.81) | TACR1TACR3RHOCRHOA | |
| SCHEMBL3203637 | 0.89 | TACR1 (0.81) | TACR1TACR3RHOCRHOA | |
| SCHEMBL8300981 | 0.89 | TACR1 (0.81) | TACR1TACR3RHOCRHOA | |
| SCHEMBL4556039 | 0.89 | TACR1 (0.81) | TACR1TACR3RHOCRHOA | |
| SCHEMBL9113036 | 0.88 | TACR1 (0.78) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL9112230 | 0.88 | TACR1 (0.78) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL13818185 | 0.87 | TACR1 (0.77) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL9111141 | 0.86 | TACR1 (0.76) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL8296860 | 0.86 | TACR1 (0.75) | TACR1TACR3RHOCRHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0739892-B1 | Chromone derivatives | NOVARTIS AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-5965562-A | TREATING DISORDERS INDUCED BY SUBSTANCE P AND MIGRAINE HEADACHE | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5935951-A | ANTAGONIST AGAINST SUBSTANCE P | NOVARTIS FINANCE CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0707006-B1 | Aroyl-piperidine derivatives | NOVARTIS AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| US-5646144-A | FOR TREATING DISORDERS IN WHICH SUBSTANCE P PLAYS A PART IN DEVELOPMENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5604247-A | NEUROKININE ANTAGONIST | CIBA-GEIGY CORPORATION (US) | 1997-02-18 | — | — | US | disclosed |
| EP-0739892-A2 | Chromone derivatives | CIBA-GEIGY AG (CH) | 1996-10-30 | — | — | EP | disclosed |
| US-5541195-A | SUBSTANCE P ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0707006-A1 | Aroyl-piperidine derivatives | CIBA-GEIGY AG (CH) | 1996-04-17 | — | — | EP | disclosed |
| EP-0532456-B1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | EP | disclosed |
| US-5310743-A | Substance P antagonist | CIBA-GEIGY CORP. (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0532456-A1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |